Product Description
Mechanisms of Action: CLDN6 Inhibitor
Novel Mechanism: Yes
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Astellas Pharma
Company Location:
Company Founding Year: 2005
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Endometrial Cancer|Ovarian Cancer|Testicular Cancer|Non-Small-Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06681870 |
1893-CL-0101 | P1 |
Withdrawn |
Ovarian Cancer|Endometrial Cancer|Non-Small-Cell Lung Cancer|Testicular Cancer |
2029-03-31 |
2024-12-13 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|